J
Jack A. Kosmicki
Researcher at Regeneron
Publications - 3
Citations - 174
Jack A. Kosmicki is an academic researcher from Regeneron. The author has contributed to research in topics: Exome & Exome sequencing. The author has an hindex of 3, co-authored 3 publications receiving 33 citations.
Papers
More filters
Journal ArticleDOI
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
Parsa Akbari,Ankit Gilani,Olukayode A. Sosina,Jack A. Kosmicki,Lori Khrimian,Yi-Ya Fang,Trikaldarshi Persaud,Victor Garcia,Dylan Sun,Alexander H. Li,Joelle Mbatchou,Adam E. Locke,Christian Benner,Niek Verweij,Nan Lin,Sakib Hossain,Kevin Agostinucci,Jonathan V. Pascale,Ercument Dirice,Michael E. Dunn,William E. Kraus,Svati H. Shah,Yii-Der Ida Chen,Jerome I. Rotter,Daniel J. Rader,Olle Melander,Christopher D. Still,Tooraj Mirshahi,David J. Carey,Jaime Berumen-Campos,Pablo Kuri-Morales,Jesus Alegre-Díaz,Jason M. Torres,Jonathan Emberson,Rory Collins,Suganthi Balasubramanian,Alicia Hawes,Marcus B. Jones,Brian Zambrowicz,Andrew J. Murphy,Charles Paulding,Giovanni Coppola,John D. Overton,Jeffrey G. Reid,Alan R. Shuldiner,Michael Cantor,Hyun Min Kang,Gonçalo R. Abecasis,Katia Karalis,Aris N. Economides,Jonathan Marchini,George D. Yancopoulos,Mark W. Sleeman,Judith Altarejos,Giusy Della Gatta,Roberto Tapia-Conyer,Michal L. Schwartzman,Aris Baras,Manuel A. R. Ferreira,Luca A. Lotta +59 more
TL;DR: In this paper, the authors sequenced the exomes of 645,626 individuals from the United Kingdom, the United States, and Mexico and estimated associations of rare coding variants with body mass index (BMI).
Journal ArticleDOI
Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals
Jack A. Kosmicki,Julie E. Horowitz,Nilanjana Banerjee,Rouel Lanche,Anthony Marcketta,Evan Maxwell,Xiaodong Bai,Dylan Sun,Joshua D. Backman,Deepika Sharma,F. S. P. Kury,Hyun Min Kang,Colm O'Dushlaine,Ashish Yadav,Adam J. Mansfield,Alexander H. Li,Kyoko Watanabe,Lauren Gurski,Shane McCarthy,Adam E. Locke,Shareef Khalid,Sean O'Keeffe,Joelle Mbatchou,Olympe Chazara,Yunfeng Huang,Erika Kvikstad,A. O'Neill,Paul Nioi,Margaret M. Parker,Slavé Petrovski,Heiko Runz,Joseph D. Szustakowski,Quanli Wang,Emily Wong,A. Cordova-Palomera,E. N. Smith,Sándor Szalma,Xiuwen Zheng,Sahar Esmaeeli,Justin W. Davis,Yi-Pin Lai,Xing Chen,Anne E. Justice,Joseph B. Leader,Tooraj Mirshahi,David J. Carey,Anurag Verma,Giorgio Sirugo,Marylyn D. Ritchie,Daniel J. Rader,Gundula Povysil,David Goldstein,Krzysztof Kiryluk,Erola Pairo-Castineira,Konrad Rawlik,Dorota Pasko,Susan P. Walker,Alison M. Meynert,Athanasios Kousathanas,Loukas Moutsianas,Albert Tenesa,Mark J. Caulfield,Richard H Scott,James F. Wilson,J. K. Baillie,Guillaume Butler-Laporte,Tomoko Nakanishi,Mark Lathrop,J. B. Richards,Martin I. Jones,Suganthi Balasubramanian,Will Salerno,A. R. Shuldiner,Jonathan Marchini,John D. Overton,Lukas Habegger,Michael N. Cantor,Jeffrey G. Reid,A. Baras,Gonçalo R. Abecasis,Manuel A. R. Ferreira +80 more
TL;DR: In this article, the authors used exome sequence data to investigate associations between rare genetic variants and seven COVID-19 outcomes in 586,157 individuals, including 20,952 with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a respiratory illness causing hospitalization or death.
Posted ContentDOI
A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19
Sumathi Sivapalasingam,D.J. Lederer,Rafia Bhore,Negin Hajizadeh,Gerard J. Criner,Romana Hosain,Adnan Mahmood,Angeliki Giannelou,Selin Somersan-Karakaya,Meagan P. O'Brien,Anita Boyapati,Janie Parrino,Bret J Musser,Emily Labriola-Tompkins,Divya Ramesh,Lisa A. Purcell,Daya Gulabani,Wendy Kampman,Alpana Waldron,Michelle N. Gong,Suraj Saggar,Steven J. Sperber,Vidya Menon,David Stein,Magdalena E. Sobieszczyk,William Park,Judith A. Aberg,Samuel M. Brown,Jack A. Kosmicki,Julie E. Horowitz,Manuel A. R. Ferreira,Aris Baras,Bari Kowal,A. Thomas DiCioccio,Bolanle Akinlade,Michael C Nivens,Ned Braunstein,Gary Herman,George D. Yancopoulos,David M. Weinreich,Sarilumab-COVID Study Team +40 more
TL;DR: In this article, the authors performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 mg or 400 mg in adults hospitalized with Covid-19.